Silence Therapeutics (SLN) to Release Quarterly Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Silence Therapeutics to post earnings of ($0.16) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Silence Therapeutics Stock Up 1.7 %

Shares of NASDAQ:SLN opened at $4.87 on Tuesday. Silence Therapeutics has a 52-week low of $4.06 and a 52-week high of $27.72. The stock’s fifty day simple moving average is $5.78 and its 200-day simple moving average is $12.07. The company has a market capitalization of $149.64 million, a P/E ratio of -3.10 and a beta of 1.05.

Analyst Ratings Changes

Several equities analysts recently commented on the company. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. The Goldman Sachs Group initiated coverage on Silence Therapeutics in a research report on Tuesday, February 11th. They issued a “sell” rating and a $6.00 target price for the company. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, January 29th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.